Literature DB >> 1992905

Laryngeal dystonia: a series with botulinum toxin therapy.

A Blitzer1, M F Brin.   

Abstract

Laryngeal dystonia is a syndrome characterized by action-induced, involuntary spasms of the laryngeal muscles. Most patients have involvement of the adductor laryngeal muscles producing uncontrolled spasms during phonation, and a "strain-strangle" speech pattern commonly termed "spastic dysphonia." Other patients have involvement of the abductor muscles producing "whispering dysphonia." Rare patients have paradoxical vocal cord motion during respiration with adductor spasms on inspiration. Over the past 5 years we have used botulinum toxin (BOTOX) to treat more than 200 patients with laryngeal dystonia. This group includes patients with adductor involvement (phonatory dystonia, recurrent laryngeal nerve section failure, respiratory dystonia) and those with abductor involvement (whispering dystonia). Patients received benefit within 24 to 72 hours, with sustained improvement for 2 to 9 months with an average of 4 months. Patients improved to an average of 90% of normal function. Clinically significant adverse effects included extended breathy dysphonia and mild choking on fluids. BOTOX has become our treatment of choice for dystonic conditions of the larynx.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992905     DOI: 10.1177/000348949110000201

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  23 in total

Review 1.  ["Off-label use" of botulinum toxin preparations in treatment of spasmodic dysphonia. Position of the German Society of Phoniatrics and Pediatric Audiology].

Authors:  M Ptok; R Schönweiler; T Nawka
Journal:  HNO       Date:  2004-01       Impact factor: 1.284

Review 2.  Paradoxical vocal cord motion disorder: past, present and future.

Authors:  Wanis H Ibrahim; Heitham A Gheriani; Ahmed A Almohamed; Tasleem Raza
Journal:  Postgrad Med J       Date:  2007-03       Impact factor: 2.401

3.  Sudden death in Lesch-Nyhan disease.

Authors:  Vladimir Kostadinov Neychev; H A Jinnah
Journal:  Dev Med Child Neurol       Date:  2006-11       Impact factor: 5.449

4.  Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia.

Authors:  P Zwirner; D Dressler; E Kruse
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

5.  The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.

Authors:  R Whurr; M Lorch; H Fontana; G Brookes; A Lees; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

6.  Bipolar radiofrequency-induced thermotherapy (rfitt) for the treatment of spasmodic dysphonia. A report of three cases.

Authors:  Marc Remacle; Isabelle Plouin-Gaudon; Georges Lawson; Jean Abitbol
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-02-26       Impact factor: 2.503

Review 7.  Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30-year experience.

Authors:  Andrew Blitzer; Mitchell F Brin; Kristina Simonyan; Laurie J Ozelius; Steven J Frucht
Journal:  Laryngoscope       Date:  2017-12-08       Impact factor: 3.325

8.  A comparison of bilateral and unilateral botulinum toxin treatments for spasmodic dysphonia.

Authors:  P Zwirner; T Murry; G E Woodson
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

9.  Botulinum toxin injection in laryngeal dyspnea.

Authors:  Virginie Woisard; Xuelai Liu; Marie Christine Arné Bes; Marion Simonetta-Moreau
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-06       Impact factor: 2.503

10.  Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study.

Authors:  Tahwinder Upile; Behrad Elmiyeh; Waseem Jerjes; Vyas Prasad; Panagiotis Kafas; Jesuloba Abiola; Bryan Youl; Ruth Epstein; Colin Hopper; Holger Sudhoff; John Rubin
Journal:  Head Face Med       Date:  2009-10-24       Impact factor: 2.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.